Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.

Publication Type:

Journal Article


Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Volume 18, Issue 11, p.3079-85 (2009)


2009, Aged, Breast Neoplasms, Case-Control Studies, Center-Authored Paper, Cohort Studies, Estrogen Replacement Therapy, Estrogens, Female, Genotype, Humans, Introns, LINKAGE DISEQUILIBRIUM, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Polymorphism, Single Nucleotide, Postmenopause, Progestins, Prognosis, Public Health Sciences Division, Receptor, Fibroblast Growth Factor, Type 2, Risk Factors, Shared Resources, Specimen Processing Core Facility, Tumor Markers, Biological


Breast cancer concern is a major reason for the recent marked reduction in use of postmenopausal hormone therapy, although equally effective means of controlling menopausal symptoms are lacking. Single nucleotide polymorphisms (SNP) in the fibroblast growth factor receptor 2 (FGFR2) gene are substantially associated with postmenopausal breast cancer risk and could influence hormone therapy effects.